Investor Centre

Investor Deck

X (Twitter)

We are pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today:

Dr. Zdanska is a highly regarded clinical leader with extensive experience in clinical trials, including drug development of novel treatments.

We are pleased to share a replay of CEO & Acting Chairman Dr Malcolm McColl’s presentation at the NWR Virtual Healthcare Conference.

Shareholders and other interested parties can view the presentation at:

We have entered into a clinical trial collaboration with leading Chinese pharma group Innovent Biologics to investigate the combination of IVX037 and their checkpoint inhibitor sintilimab in difficult to treat cancers:

Load More

Environmental, Social, and Governance (ESG) Commitment

ImmVirX is developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations. The first virus is in clinical studies with further agents in pre-clinical development. Its novel oncolytic immunotherapy harnesses the power of viruses to preferentially infect and kill cancer cells and increase the effectiveness of current immunotherapy treatments in fighting cancers of high unmet need including colorectal, gastric, ovarian and liver cancer.

The board of ImmVirX recognises the important of embedding ESG principles as part of its operations and values, even in the early, research and development phase of its growth. This statement describes our commitment to ESG, highlighting the material factors which the board considers fundamental to the long-term success of a company’s ESG strategy.


Environmental Stewardship

The company seeks to minimize its environmental footprint by implementing sustainable practices across its operations, while recognising that we do not yet operate at a commercial scale. We have no internal manufacturing capability and maintain a single research facility. We operate in a specialised and highly regulated industry with limited choice of qualified vendors. We strive to reduce waste, conserve resources, and explore environmentally friendly alternatives in our research and development processes. Environmental impact from operations is not presently considered material to our ESG strategy however we also recognise that, as the company expands, an increased focus on managing environmental footprint will yield more substantial environmental advantage than is presently possible.

Social Responsibility

Social good is at the centre of the company’s mission which is to improve human health, specifically ‘to develop novel oncolytic viruses to improve the clinical benefit of immune checkpoint inhibitors in some of the most challenging and prevalent cancer types globally’.

The company is conducting clinical trials of its investigational therapy. Patient safety is paramount in these studies. The trial programme is presently located in Australia under highly regulated conditions.  The programme will only be expanded into jurisdictions where the company has confidence that patient safety and rights will be protected within a strong regulatory environment.

We engage closely with healthcare professionals to ensure our innovations address the clinical needs of patients both through increased life expectancy and quality of life.

We are dedicated to fostering inclusivity and diversity within our workforce and promoting employee well-being and inclusion in the company’s mission. The company does not apply quotas in our approach to recruitment. We recruit and manage staff with a focus on talent and passion for our mission and remain mindful of unconscious bias in our selection process. Through this approach we are confident that we retain an inclusive, diverse and talented team which is committed to delivery of our mission.




ImmVirX upholds high standards of governance, promoting transparency, accountability, and ethical behaviour in all aspects of our business as prescribed in our Code of Conduct [. The company is not listed on the Australian Stock Exchange but nonetheless seeks to adopt its Principles and Recommendations for Good Governance Practice, to the extent possible within our circumstances.

Good governance relies on the tone set by the board of directors.  The company retains a strong and well qualified board which prioritises good governance. This includes maintenance of sound risk management practices; maintaining clear and transparent communication with stakeholders (including shareholders, employees, regulators and the healthcare community) and strong oversight of the standards of behaviour prescribed in our Code of Conduct. These governance practices are designed to ensure the responsible and sustainable growth of the company while adhering to legal and regulatory requirements.

Innovation for Impact

We recognize the urgent need for breakthroughs in cancer treatment, especially in cases where existing immunotherapies have limitations. ImmVirX is dedicated to fostering a culture of innovation within our organization. We invest in cutting-edge research and development to bring forward novel therapies that have the potential to redefine the landscape of cancer treatment, ultimately making a positive impact on patients’ lives.


ImmVirX is committed to the principles of ESG as being critical to building long term enterprise value in a way which also addresses the societal priorities enshrined in the United Nations’ Sustainable Development Goals. We recognise ESG is a journey and that we need to adapt and build our commitment in accordance with the growth of our business. This statement focuses on those ESG components considered material for the company in its present stage of development.

We believe that by integrating environmental, social, and governance principles into our core business strategy, we can create enduring value for our stakeholders while advancing the fight against cancer and improving outcomes for patients facing challenging diagnoses.